Literature DB >> 30844663

IL-1α and IL-6 predict vascular events or death in patients with cerebral small vessel disease-Data from the SHEF-CSVD study.

Jacek Staszewski1, Ewa Skrobowska2, Renata Piusińska-Macoch3, Bogdan Brodacki3, Adam Stępień3.   

Abstract

PURPOSE: The natural clinical course of cerebral small vessel disease (CSVD) was not thoroughly described. The aim of this single center cohort study was to establish biochemical predictors of vascular events and death in CSVD patients during a 24-month follow-up. PATIENTS AND METHODS: A total of 130 functionally independent patients with marked MRI features of CSVD and recent lacunar stroke (n = 52,LS), vascular Parkinsonism (n = 28,VaP) or dementia (n = 50,VaD) were prospectively recruited. Serum markers of endothelial dysfunction, inflammation and hemostasis were determined at baseline. The primary outcome was defined as occurrence of death or any vascular events during the observation.
RESULTS: The mean age was 72 ± 8.1 years, and 37.6% of the patients were women. The mean follow-up time was 22.3 ± 4.3 months, and 84.6% of patients had extensive white matter lesions on baseline MRI. The overall mortality rate was 6.9%, and vascular events or death occurred in 27% of the patients. Kaplan-Meier survival curves revealed no significant differences between CSVD groups (log rank p = 0.49). Cox regression analysis revealed that IL-1α (HR 1.4; 95%CI 1.09-1.8), IL-6 (1.4;1.1-2.2), hs-CRP (1.1;1.06-1.9), homocysteine (1.4;1.1-1.8), fibrinogen (1.4;1.05-2), and d-dimer (2.7;1.6-4.5) were significantly associated with the primary outcome. IL-1α (1.3;1.07-1.8), IL-6 (1.4;1.02-2.2), d-dimer (2.8;1.6-5) and homocysteine (1.4;1.1-1.8) remained significant after adjusting for age, sex and CSVD radiological markers.
CONCLUSIONS: Our study demonstrated the important prognostic role of various circulation markers of inflammation in individuals with different clinical signs and radiological markers of CSVD. The strongest association occurred between IL-1α, IL-6 and recurrent stroke, other vascular events and death.
Copyright © 2019 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cerebral small vessel disease; Interleukins; Lacunar stroke; Parkinsonism; Vascular dementia

Mesh:

Substances:

Year:  2019        PMID: 30844663     DOI: 10.1016/j.advms.2019.02.003

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN: 1896-1126            Impact factor:   3.287


  5 in total

Review 1.  Emerging Biomarkers in Vascular Cognitive Impairment and Dementia: From Pathophysiological Pathways to Clinical Application.

Authors:  Virginia Cipollini; Fernanda Troili; Franco Giubilei
Journal:  Int J Mol Sci       Date:  2019-06-08       Impact factor: 5.923

2.  Corneal nerve loss in patients with TIA and acute ischemic stroke in relation to circulating markers of inflammation and vascular integrity.

Authors:  Adnan Khan; Aijaz Parray; Naveed Akhtar; Abdelali Agouni; Saadat Kamran; Sajitha V Pananchikkal; Ruth Priyanka; Hoda Gad; Georgios Ponirakis; Ioannis N Petropoulos; Kuan-Han Chen; Kausar Tayyab; Maher Saqqur; Ashfaq Shuaib; Rayaz A Malik
Journal:  Sci Rep       Date:  2022-02-28       Impact factor: 4.379

Review 3.  Biomarkers involved in the pathogenesis of cerebral small-vessel disease.

Authors:  Xiaolu Liu; Pei Sun; Jing Yang; Yuhua Fan
Journal:  Front Neurol       Date:  2022-09-01       Impact factor: 4.086

4.  Mesenchymal Stem Cell Exosomal miR-146a Mediates the Regulation of the TLR4/MyD88/NF-κB Signaling Pathway in Inflammation due to Diabetic Retinopathy.

Authors:  Cao Gu; Hongjun Zhang; Shaofei Zhao; Daotong He; Yu Gao
Journal:  Comput Math Methods Med       Date:  2022-06-18       Impact factor: 2.809

5.  An IL-18-centered inflammatory network as a biomarker for cerebral white matter injury.

Authors:  Marie Altendahl; Pauline Maillard; Danielle Harvey; Devyn Cotter; Samantha Walters; Amy Wolf; Baljeet Singh; Visesha Kakarla; Ida Azizkhanian; Sunil A Sheth; Guanxi Xiao; Emily Fox; Michelle You; Mei Leng; David Elashoff; Joel H Kramer; Charlie Decarli; Fanny Elahi; Jason D Hinman
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.